Concomitant Therapy of Inactivated CECT7121 with Fluoroquinolones in a Enteritidis Murine Sepsis Model.

Optimization of existing antimicrobial therapies is a strategy proposed for extending antimicrobial activity and delaying resistance development. This study aimed to assess the effect of inactivated CECT7121 (I-EFCECT7121) in a combined therapy with Enrofloxacin or Ciprofloxacin in a Enteritidis murine sepsis model. Firstly, dose titration studies were performed to set up: (a) Enteritidis (SE) Lethal dose 99 (LD99) and (b) safety of I-EFCECT7121 (c) I-EFCECT7121 dosage scheme. Then, I-EFCECT7121 in combined therapy with 4 doses (5 mg/kg) per 12 h of CFX and EFX in an LD99 BALB/c infection, were evaluated. Survival rate was monitored for 20 days in order to estimate the treatment success. The efficacy of both drugs was improved by combining them with the inactivated bacteria. However, only a significant increase ( < 0.05) was observed after I-EFCECT7121 and CFX combined treatment (40% of survival rate). By contrast, each drug alone achieved a 10% of survival rate. These outcomes showed a potential therapeutic synergism when I-EFCECT7121 was concomitantly given with ciprofloxacin.